Fluidigm Corporation logo
Fluidigm Corporation FLDM

Fluidigm Corporation Income Statement 2020-2011 | FLDM

Brief overview of profit and loss at Fluidigm Corporation

The conclusions below are based on five years of reported results. Revenue at Fluidigm Corporation moved from $115 million in 2015 to $138 million in 2020. The total change was +20.4%, with a CAGR of approximately 3.8%. Revenue was effectively stagnant over the period.

Gross profit was $68.1 million at the start and $83.3 million at the end of the period (+22.4%). At the margin level, the figure shifted from 59.4% to 60.3%. Gross profitability remained broadly stable.

The five-year EBITDA result moved by +7.7%: from −38 million dollars to −35.1 million dollars. EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin moved from −33.1% to −25.4%. The increased EBITDA share is a positive sign.

Net income moved from −$53.3 million at the start to −$53 million at the end. Losses became smaller, but the business remains unprofitable.

The market value of the business moved from 193 million dollars to 481 million dollars, or +149.8%. Investor expectations increased faster than reported performance.

Overall conclusion

The financial profile remains mixed, with strengths and risks moving in different directions. The positive side is supported by higher operating efficiency, a steady final result and a stable gross margin. The weaker side of the profile includes limited revenue growth and a low EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.

Annual Income Statement Fluidigm Corporation

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

481 M 262 M 340 M 216 M 175 M 193 M 1.07 B 1.14 B 361 M 264 M

Shares

74.3 M 66.8 M 39.7 M 33 M 29 M 28.7 M 27.8 M 25.5 M 22.1 M 17.8 M

Net Income

-53 M -64.8 M -59 M -60.5 M -76 M -53.3 M -52.8 M -16.5 M -19 M -22.5 M

Revenue

138 M 117 M 113 M 102 M 104 M 115 M 116 M 71.2 M 52.3 M 42.9 M

EBITDA

-35.1 M -36 M -31.6 M -39.8 M -55.3 M -38 M -27.3 M -14.8 M -15.9 M -14.5 M

Operating Expenses

134 M 116 M 110 M 110 M 132 M 122 M 115 M 68.4 M 55.1 M 45.2 M

General and Administrative Expenses

97.9 M 84.5 M 79.8 M 79.5 M 93.2 M 83 M 71.3 M 48.4 M 38.5 M 31.3 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Fluidigm Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Anixa Biosciences Anixa Biosciences
ANIX
$ 2.81 1.63 % $ 91.2 K usaUSA
Biodesix Biodesix
BDSX
$ 27.49 1.95 % $ 208 M usaUSA
Biomerica Biomerica
BMRA
$ 2.4 5.96 % $ 7 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.35 10.66 % $ 7.35 M usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 11.67 5.68 % $ 123 M chinaChina
Bioventus Bioventus
BVS
$ 13.22 1.85 % $ 881 M usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 52.37 4.21 % $ 2.79 B usaUSA
Celcuity Celcuity
CELC
$ 83.55 0.12 % $ 3.91 B usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 1.14 1.79 % $ 1.52 M usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 269.48 0.06 % $ 13.4 B usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 33.22 2.74 % $ 963 M usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 239.32 1.83 % $ 26.6 B usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 202.7 1.28 % $ 144 B usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 7.1 2.31 % $ 28.3 M israelIsrael
Fulgent Genetics Fulgent Genetics
FLGT
$ 20.56 0.54 % $ 633 M usaUSA
Guardant Health Guardant Health
GH
$ 165.87 5.39 % $ 20.8 B usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 169.34 0.02 % $ 13.3 B irlandaIrlanda
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 509.72 0.99 % $ 41 B usaUSA
Illumina Illumina
ILMN
$ 207.94 0.72 % $ 32.2 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 264.81 1.16 % $ 45.5 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 314.56 0.95 % $ 26.2 B usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 100.27 0.02 % $ 6.77 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 591.17 0.62 % $ 17.1 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 287.94 1.01 % $ 26.5 B schweizSchweiz
Myriad Genetics Myriad Genetics
MYGN
$ 3.74 9.36 % $ 346 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 5.68 0.98 % $ 4.47 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 18.27 5.51 % $ 2.34 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 11.87 0.72 % $ 2.58 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 22.14 4.83 % $ 496 M usaUSA
Natera Natera
NTRA
$ 339.13 3.1 % $ 46.4 B usaUSA
OPKO Health OPKO Health
OPK
$ 1.55 0.38 % $ 1.16 B usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.36 4.23 % $ 408 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 25.15 2.28 % $ 23.8 B niderlandNiderland
Personalis Personalis
PSNL
$ 16.3 0.52 % $ 1.45 B usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Senseonics Holdings Senseonics Holdings
SENS
$ 8.88 1.95 % $ 371 M usaUSA
Neuronetics Neuronetics
STIM
$ 2.89 5.61 % $ 191 M usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 611.62 0.3 % $ 231 B usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 136.05 6.94 % $ 8.14 B usaUSA
VolitionRx Limited VolitionRx Limited
VNRX
$ 0.31 0.34 % $ 39 M singaporeSingapore
Waters Corporation Waters Corporation
WAT
$ 407.54 1.67 % $ 24.3 B usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
- - $ 1.49 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA